10 results on '"Alessandri, Francesco"'
Search Results
2. Reduced Reliability of Procalcitonin (PCT) as a Biomarker of Bacterial Superinfection: Concerns about PCT-Driven Antibiotic Stewardship in Critically Ill COVID-19 Patients—Results from a Retrospective Observational Study in Intensive Care Units.
- Author
-
Ceccarelli, Giancarlo, Alessandri, Francesco, Migliara, Giuseppe, Baccolini, Valentina, Giordano, Giovanni, Galardo, Gioacchino, Marzuillo, Carolina, De Vito, Corrado, Russo, Alessandro, Ciccozzi, Massimo, Villari, Paolo, Venditti, Mario, Mastroianni, Claudio M., Pugliese, Francesco, and d'Ettorre, Gabriella
- Subjects
- *
COVID-19 , *INTENSIVE care units , *CRITICALLY ill , *CALCITONIN , *ANTIMICROBIAL stewardship , *NEONATAL sepsis - Abstract
Background: The aim of this study was to assess whether procalcitonin levels is a diagnostic tool capable of accurately identifying sepsis and ventilator-associated pneumonia (VAP) even in critically ill COVID-19 patients. Methods: In this retrospective, observational study, all critically ill COVID-19 patients who survived for ≥2 days in a single university hospital and had at least one serum procalcitonin (PCT) value and associated blood culture and/or culture from a lower respiratory tract specimen available were eligible for the study. Results: Over the research period, 184 patients were recruited; 67 VAP/BSI occurred, with an incidence rate of 21.82 episodes of VAP/BSI (95% CI: 17.18–27.73) per 1000 patient-days among patients who were included. At the time of a positive microbiological culture, an average PCT level of 1.25–3.2 ng/mL was found. Moreover, also in subjects without positive cultures, PCT was altered in 21.7% of determinations, with an average value of 1.04–5.5 ng/mL. Both PCT and PCT-72 h were not linked to a diagnosis of VAP/BSI in COVID-19 patients, according to the multivariable GEE models (aOR 1.13, 95% CI 0.51–2.52 for PCT; aOR 1.32, 95% CI 0.66–2.64 for PCT-72 h). Conclusion: Elevated PCT levels might not always indicate bacterial superinfections or coinfections in a severe COVID-19 setting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Clinical Impact of COVID-19 on Multi-Drug-Resistant Gram-Negative Bacilli Bloodstream Infections in an Intensive Care Unit Setting: Two Pandemics Compared.
- Author
-
Cogliati Dezza, Francesco, Arcari, Gabriele, Alessi, Federica, Valeri, Serena, Curtolo, Ambrogio, Sacco, Federica, Ceccarelli, Giancarlo, Raponi, Giammarco, Alessandri, Francesco, Mastroianni, Claudio Maria, Venditti, Mario, and Oliva, Alessandra
- Subjects
INTENSIVE care units ,PANDEMICS ,COVID-19 ,SEPTIC shock ,GRAM-negative bacteria - Abstract
Two mutually related pandemics are ongoing worldwide: the COVID-19 and antimicrobial resistance pandemics. This study aims to evaluate the impact of COVID-19 on multi-drug-resistant Gram-negative bacteria (MDR-GN) bloodstream infections (BSIs) in a single intensive care unit (ICU). We conducted a retrospective study including patients admitted to the ICU, reorganized for COVID-19 patients' healthcare, with at least one confirmed MDR-GN BSI during 2019–2020. We compared clinical and microbiological features, incidence density, antibiotic therapy and mortality rate in pre- and during-COVID-19 pandemic periods. We estimated the impact of COVID-19 on mortality by means of univariate Cox regression analyses. A total of 46 patients were included in the study (28 non-COVID-19/18 COVID-19). Overall, 63 BSI episodes occurred (44/19), and non-COVID-19 patients had a higher incidence of MDR-GN BSIs and were more likely to present K. pneumoniae BSIs, while the COVID-19 group showed more A. baumannii BSIs with higher per pathogen incidence. COVID-19 patients presented more critical conditions at the BSI onset, a shorter hospitalization time from BSI to death and higher 30-day mortality rate from BSI onset. COVID-19 and septic shock were associated with 30-day mortality from MDR-GN BSIs, while early active therapy was a protective factor. In conclusion, COVID-19 showed a negative impact on patients with MDR-GN BSIs admitted to the ICU. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Klebsiella pneumoniae infections in COVID-19 patients: a two-month retrospective analysis in an Italian hospital
- Author
-
Arcari, Gabriele, Raponi, Giammarco, Sacco, Federica, Bibbolino, Giulia, Lella, Federica Maria Di, Alessandri, Francesco, Coletti, Monica, Trancassini, Maria, Deales, Alberto, Pugliese, Francesco, Antonelli, Guido, and Carattoli, Alessandra
- Subjects
COVID-19 ,Hospital Acquired Infections ,Intensive Care Unit ,carbapenemase - Published
- 2020
5. Acinetobacter baumannii Isolates from COVID-19 Patients in a Hospital Intensive Care Unit: Molecular Typing and Risk Factors.
- Author
-
Ceparano, Mariateresa, Baccolini, Valentina, Migliara, Giuseppe, Isonne, Claudia, Renzi, Erika, Tufi, Daniela, De Vito, Corrado, De Giusti, Maria, Trancassini, Maria, Alessandri, Francesco, Ceccarelli, Giancarlo, Pugliese, Francesco, Villari, Paolo, Angiulli, Maria, Battellito, Stefania, Bellini, Arianna, Bongiovanni, Andrea, Caivano, Lucilla, Castellani, Marta, and Coletti, Monica
- Subjects
INTENSIVE care units ,COVID-19 ,INTENSIVE care patients ,ACINETOBACTER baumannii ,PULSED-field gel electrophoresis ,ACINETOBACTER infections - Abstract
Infections caused by Acinetobacter baumannii represent a major concern for intensive care unit (ICU) patients. However, the epidemiology of these infections among COVID-19 patients has not been fully explored. The aims of this study were (i) to characterize the clonal spread of A. baumannii among COVID-19 patients admitted to the ICU of the Umberto I hospital of Rome during the first year of the pandemic and (ii) to identify risk factors for its acquisition. Isolates were analysed by pulsed-field gel electrophoresis, and a multivariable regression model was constructed. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated. Overall, 193 patients were included, and 102 strains were analysed. All isolates had highly antibiotic-resistant profiles and derived from two genotypes. The cumulative incidence of A. baumannii acquisition (colonization or infection) was 36.8%. Patients with A. baumannii had higher mortality and length of stay. Multivariable analysis showed that previous carbapenem use was the only risk factor associated with A. baumannii acquisition (aOR: 4.15, 95% CI: 1.78–9.64). We documented substantial A. baumannii infections and colonization and high levels of clonal transmission. Given the limited treatment options, effective prevention and containment strategies to limit the spread of A. baumannii should be implemented. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. The role of teicoplanin in the treatment of SARS‐CoV‐2 infection: A retrospective study in critically ill COVID‐19 patients (Tei‐COVID study).
- Author
-
Ceccarelli, Giancarlo, Alessandri, Francesco, Oliva, Alessandra, Borrazzo, Cristian, Dell'Isola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Pelli, Massimiliano, Raponi, Giammarco, Turriziani, Ombretta, Ruberto, Franco, Rocco, Monica, Pugliese, Francesco, Russo, Alessandro, d'Ettorre, Gabriella, and Venditti, Mario
- Subjects
COVID-19 ,TEICOPLANIN ,SARS-CoV-2 ,CRITICALLY ill ,LEUKOCYTE count - Abstract
Teicoplanin has a potential antiviral activity expressed against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and was suggested as a complementary option to treat coronavirus disease 2019 (COVID‐19) patients. In this multicentric, retrospective, observational research the aim was to evaluate the impact of teicoplanin on the course of COVID‐19 in critically ill patients. Fifty‐five patients with severe COVID‐19, hospitalized in the intensive care units (ICUs) and treated with best available therapy were retrospectively analysed. Among them 34 patients were also treated with teicoplanin (Tei‐COVID group), while 21 without teicoplanin (control group). Crude in‐hospital Day‐30 mortality was lower in Tei‐COVID group (35.2%) than in control group (42.8%), however not reaching statistical significance (p =.654). No statistically significant differences in length of stay in the ICU were observed between Tei‐COVID group and control group (p =.248). On Day 14 from the ICU hospitalization, viral clearance was achieved in 64.7% patients of Tei‐COVID group and 57.1% of control group, without statistical difference. Serum C‐reactive protein level was significantly reduced in Tei‐COVID group compared to control group, but not other biochemical parameters. Finally, Gram‐positive were the causative pathogens for 25% of BSIs in Tei‐COVID group and for 70.6% in controls. No side effects related to teicoplanin use were observed. Despite several limitations require further research, in this study the use of teicoplanin is not associated with a significant improvement in outcomes analysed. The antiviral activity of teicoplanin against SARS‐CoV‐2, previously documented, is probably more effective at early clinical stages. Highlights: ‐Evidence from the scientific literature highlighted that a number of glycopeptide antibiotics have a potential antiviral activity expressed against Coronaviruses. Based on the aforementioned, teicoplanin was suggested as an alternative complementary option to treat also SARS‐CoV‐2 infected patients‐Teicoplanin also remain a possible choice for treatment of Staphylococcus aureussuperinfection, a major complication of respiratory viral infections and in COVID related pneumonia.‐This is the first multicentric, retrospective, observational analysis of a real‐life cohort of critically ill patients with COVID‐19 complementary treated with teicoplanin, used with a double purpose: as empiric antibiotic treatment and as antiviral agent (Tei‐COVID group). A control group untreated with teicoplanin was also enrolled‐The results of this study showed that teicoplanin does not impact on the crude mortality in critically ill COVID‐19 patients: the primary outcome of the study failed due to lack of statistical significance despite mortality being lower in the Tei‐COVID group than in the control group (35.2% vs. 42.8%)‐On Day 14 from the ICU hospitalization, viral clearance was achieved in 64.7% patients of Tei‐COVID group and 57.1% of control group, without statistical difference.‐Serum C‐reactive protein level was significantly reduced in Tei‐COVID group compared to control group. No statistically significant differences were observed for white blood cells and lymphocytes counts, kidney and liver function, PO2/FiO2 and weaning from mechanical ventilation between the two groups at day 8.‐ A possible explanation for these findings is that the antiviral activity of a drug is considered more effective at the onset of disease when viral replication and direct viral damage are still significant. As the disease progresses (the study enrolled critically ill patients), the damage is progressively sustained by pathogenic mechanisms not directly correlated with the presence of the virus, thus reducing the potential therapeutic role of antivirals at this stage. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Comparing the Occurrence of Healthcare-Associated Infections in Patients with and without COVID-19 Hospitalized during the Pandemic: A 16-Month Retrospective Cohort Study in a Hospital Intensive Care Unit.
- Author
-
Isonne, Claudia, Baccolini, Valentina, Migliara, Giuseppe, Ceparano, Mariateresa, Alessandri, Francesco, Ceccarelli, Giancarlo, Tellan, Guglielmo, Pugliese, Francesco, De Giusti, Maria, De Vito, Corrado, Marzuillo, Carolina, Villari, Paolo, Barone, Lavinia Camilla, Giannini, Dara, Marotta, Daniela, Marte, Mattia, Mazzalai, Elena, Germani, Irma, Bellini, Arianna, and Bongiovanni, Andrea
- Subjects
COVID-19 ,INTENSIVE care units ,HOSPITAL care ,PANDEMICS ,COVID-19 pandemic - Abstract
The COVID-19 pandemic has increased the healthcare-associated infection (HAI) risk in intensive care unit (ICU) patients. However, a comparison between patients with and without COVID-19 in terms of HAI incidence has been rarely explored. In this study, we characterized the occurrence of HAI among patients with and without COVID-19 admitted to the ICU of the Umberto I hospital of Rome during the first 16 months of the pandemic and also identified risk factors for HAI acquisition. Patients were divided into four groups according to their ICU admission date. A multivariable conditional risk set regression model for multiple events was constructed for each admission period. Adjusted hazard ratios and 95% confidence intervals were calculated. Overall, 352 COVID-19 and 130 non-COVID-19 patients were included, and a total of 361 HAIs were recorded. We found small differences between patients with and without COVID-19 in the occurrence and type of HAI, but the infections in the two cohorts mostly involved different microorganisms. The results indicate that patient management was likely an important factor influencing the HAI occurrence during the pandemic. Effective prevention and control strategies to reduce HAI rates should be implemented. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Impact of continuous renal replacement therapy (CRRT) and other extracorporeal support techniques on procalcitonin guided antibiotic therapy in critically ill patients with septic shock.
- Author
-
Ceccarelli, Giancarlo, Spaziante, Martina, Venditti, Mario, Alessandri, Francesco, Sargentini, Valeria, Bachetoni, Alessandra, D'Alessandro, Maria Domenica, and Morabito, Santo
- Subjects
CRITICALLY ill ,SEPTIC shock - Published
- 2019
- Full Text
- View/download PDF
9. Prior Antibiotic Therapy and the Onset of Healthcare-Associated Infections Sustained by Multidrug-Resistant Klebsiella pneumoniae in Intensive Care Unit Patients: A Nested Case–Control Study.
- Author
-
Migliara, Giuseppe, Baccolini, Valentina, Isonne, Claudia, Cianfanelli, Sara, Di Paolo, Carolina, Mele, Annamaria, Lia, Lorenza, Nardi, Angelo, Salerno, Carla, Caminada, Susanna, Cammalleri, Vittoria, Alessandri, Francesco, Tellan, Guglielmo, Ceccarelli, Giancarlo, Venditti, Mario, Pugliese, Francesco, Marzuillo, Carolina, De Vito, Corrado, De Giusti, Maria, and Villari, Paolo
- Subjects
INTENSIVE care patients ,KLEBSIELLA pneumoniae ,KLEBSIELLA infections ,ANTIBIOTICS ,CASE-control method ,INTENSIVE care units - Abstract
Epidemiological research has demonstrated direct relationships between antibiotic consumption and the emergence of multidrug-resistant (MDR) bacteria. In this nested case–control study, we assessed whether prior exposure to antibiotic therapy and its duration affect the onset of healthcare-associated infections (HAIs) sustained by MDR Klebsiella pneumoniae (MDR-Kp) in intensive care unit patients. Cases were defined as patients who developed an MDR-Kp HAI. Controls matched on sex and the length of intensive care unit (ICU) stay were randomly selected from the at-risk population. Any antibiotic agent received in systemic administration before the onset of infection was considered as antibiotic exposure. Multivariable conditional logistic regression analyses were performed to estimate the effect of prior exposure to each antibiotic class (Model 1) or its duration (Model 2) on the onset of HAIs sustained by MDR-Kp. Overall, 87 cases and 261 gender-matched controls were compared. In Model 1, aminoglycosides and linezolid independently increased the likelihood of developing an MDR-Kp HAI, whereas exposure to both linezolid and penicillins reduced the effect of linezolid alone. In Model 2, cumulative exposure to aminoglycosides increased the likelihood of the outcome, as well as cumulative exposures to penicillins and colistin, while a previous exposure to both penicillins and colistin reduced the influence of the two antibiotic classes alone. Our study confirms that aminoglycosides, penicillins, linezolid, and colistin may play a role in favoring the infections sustained by MDR-Kp. However, several double exposures in the time window before HAI onset seemed to hinder the selective pressure exerted by individual agents. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital.
- Author
-
Arcari, Gabriele, Raponi, Giammarco, Sacco, Federica, Bibbolino, Giulia, Di Lella, Federica Maria, Alessandri, Francesco, Coletti, Monica, Trancassini, Maria, Deales, Alberto, Pugliese, Francesco, Antonelli, Guido, and Carattoli, Alessandra
- Subjects
- *
KLEBSIELLA , *KLEBSIELLA infections , *KLEBSIELLA pneumoniae , *COVID-19 , *SARS-CoV-2 - Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.